Skip to main content

Exploiting the pathophysiology of the gut towards innovative oral peptide delivery strategies

Project description

Bioactive nanocarriers as an oral peptide delivery strategy

Development of a novel oral drug delivery system for therapeutic peptides is a major challenge in the treatment of chronic diseases such as type 2 diabetes. This EU-funded project will work on the application of nanocarriers for peptide delivery, which protects its cargo against chemical and enzymatic degradation while enabling controlled release, targeting and increased bio-availability. Project strategy stems from an earlier observation that lipid-based nanocarriers themselves trigger endogenous bio-active peptide secretion in vivo after oral administration to mice. Current research will aim to develop a dual-action delivery system that combines the biological effect of the nanocarriers and that of the encapsulated drug to enable complex and very efficient treatments for gastrointestinal disorders.

Call for proposal

ERC-2019-STG
See other projects for this call

Funding Scheme

ERC-STG - Starting Grant

Host institution

UNIVERSITE CATHOLIQUE DE LOUVAIN
Address
Place De L Universite 1
1348 Louvain La Neuve
Belgium
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 488 937,50

Beneficiaries (1)

UNIVERSITE CATHOLIQUE DE LOUVAIN
Belgium
EU contribution
€ 1 488 937,50
Address
Place De L Universite 1
1348 Louvain La Neuve
Activity type
Higher or Secondary Education Establishments